Participant flow

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer · Source last updated 2019-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Gleevec™ 600 mg QD po continuously (a cycle will be defined as 28 days). If first cycle of Gleevec™ at 600 mg QD is tolerated without any significant toxicity, the dose can be escalated to 400 mg BID po Q 12 hours until disease progression or adverse effects prohibit further therapy.

   id

   FG000

   title

   Gleevec

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Ineligible: wrong primary

   2. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Never treated

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         26

      type

      STARTED

   2. achievements

      1. comment

         Eligible and treated patients.

         group Id

         FG000

         num Subjects

         23

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         3

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

The study was activated on 1/5/2004 and closed to accrual on 8/1/2005.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice